The Change Initiative Prevention Programme, delivered in partnership with leading global actors, aims to reframe prevention ...

Ultimately the plan will be judged by its real-world impact on health outcomes. At this years’ OHE Annual Lecture in September, Professor Anita Charlesworth will offer reflections on the economic ...

At the intersection of health and the climate is an urgent crisis. This crisis affects health in ways that are wide-ranging, ...

Antimicrobial resistance (AMR) is an urgent global health crisis. AMR infections cause an estimated 1.3 million deaths globally every year, and this number is only projected to rise.

In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced ...

The EU Commission has set out important but controversial proposals for an AMR pull incentive for new antibiotics. In the first of this insight series, we set out seven objectives an EU ...

A biennial prize fund to promote thought leadership around the big questions affecting health economics. OHE’s educational mission is to support, sustain, and enhance the discipline of health ...

The value of antibiotics often extends beyond what HTA captures. The STEDI framework aims to capture that broader value and our report outlines a roadmap to realising its full potential.

Digital Health Technologies are a major trend in health care, and successfully adding them to the wider portfolio of health technologies requires coordinated involvement from various stakeholders.

In this report, we highlight the significance of prevention as a cost-effective and often cost-saving investment for public sector resources. Prevention, covering primary, secondary, and tertiary ...

Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers and HTA bodies. Antimicrobial ...